The trajectory of the erectile dysfunction drug presents a complex picture for investors. While the initial release generated massive gains, the lapse of its exclusive rights opened the floodgates to off-brand versions, dramatically reducing sales. This creates a particular risk for pharmaceutical companies banking on comparable blockbuster product

The legacy of Viagra, and its developer copyright, presents a complex case study for investors. Originally a blockbuster drug, producing billions in revenue , its patent expiration created a deluge of generic competition , significantly eroding its position . While certain firms may seek to capitalize on related treatments , the existing landscape